Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 8
Submit an article Journal homepage
171
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

A retrospective single-center analysis of CD-19 directed CAR T-cell therapy in relapsed/refractory mantle cell lymphoma

Titas BanerjeeDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAORCID Iconhttps://orcid.org/0000-0001-8077-7888View further author information
ORCID Icon,
Matthew NewmanDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information
,
Andy ChenDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information
,
Richard T. MaziarzDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information
,
Levanto SchachterDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information
,
Stephen E. SpurgeonDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USAView further author information
&
Anusha VallurupalliDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5003-807XView further author information
ORCID Icon show all
Pages 1472-1475 | Received 03 Mar 2023, Accepted 19 Apr 2023, Published online: 07 Jun 2023

References

  • McCulloch R, Lewis D, Crosbie N, et al. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. Br J Haematol. 2021;193(2):290–298.
  • Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559–1563.
  • Jain P, Wang ML. Mantle cell lymphoma in 2022—a comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022;97(5):638–656.
  • Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–1342.
  • Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–638.
  • Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
  • Daniel D, Sjoberg MB. Steven Haesendonckx, Tim Treis. ggsurvfit: flexible Time-to-Event Figures; 2022.
  • Therneau TM. A package for survival analysis in R; 2023. Available from: https://CRAN.R-project.org/package=survival
  • Gloria Iacoboni KR, Villacampa G, van Doesum JA, et al. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2022;6(12):3606–3610.
  • Wang Y, Jain P, Locke FL, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2023;41(14):2594–2606.
  • Wang M, Munoz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41(3):555–567.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.